Skip to main content
. 2017 Aug 7;8(52):89566–89579. doi: 10.18632/oncotarget.20023

Figure 7. Inhibition of K562 tumor growth in a mouse xenograft model.

Figure 7

Tumors were initiated by subcutaneous injection of K562 cells in to the flank of each mouse and were treated intratumourally with HXR9 or CXR9 at a dose of 50 mg/Kg, or Ro31 at a dose of 10 mg/Kg, or both HXR9 and Ro31, every 3 days.